Tiziana Life Sciences Ltd is a clinical-stage biotechnology company. The Company specializes in developing transformative therapies for neurodegenerative diseases and gastrointestinal diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Crohn’s Disease and KRAS+ NSCLC. The Company’s lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Crohn’s disease, Pro-MS and autoimmune diseases, and its Milciclib (TZLS-201), is an orally bioavailable, small molecule, spectrum inhibitor of cyclin-dependent kinases (CDKs) (a family of highly conserved enzymes that regulate the cell cycle and cell division) and Src family kinases, which involved in regulating cell growth and potential transformation of normal cells to cancer cells. The Company is also focused on Anti Interlukin-6 Receptor mAB (TZLS-501), which is a fully human mAb that binds to both membrane-bound and soluble forms of IL-6R.